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Aim: To investigate the effects of muscle denervation and the introduction of the β2-adrenoceptor agonist, formoterol, on the 
relationship between muscles and underlying skeletal growth.
Method: Thirty-one (4-week-old) male Sprague-Dawley rats were assigned to four groups: Surgical Sham; Denervated; 
Denervated + β2-agonist; and β2-agonist only. The Surgical Sham group had the left masseteric nerve exposed but not 
sectioned. Both of the denervated groups had the left masseteric nerve exposed and sectioned. The groups receiving the β2-
agonist had formoterol directly injected into the left masseter muscle every three days for eight weeks. Sixteen angular and linear 
skeletal measurements were assessed in the overall craniofacial region and the mandible via standardised digital radiography in 
three views: lateral head, submento-vertex and right and left disarticulated hemi-mandibles.
Results: The findings indicated that, following surgical denervation of the masseter muscle, there were significant changes in the 
muscle and in the subsequent development of the underlying skeletal structures. The post-surgical changes were largely offset by 
the administration of a β2-agonist, formoterol, which attenuated muscle atrophy. However, the administration of the β2-agonist 
only, without surgical denervation, did not lead to changes in skeletal facial form.
Conclusions: Denervation atrophy of the masseter muscle results in statistically significant changes in the development of the 
underlying skeleton. The changes, however, are localised to areas of muscle attachment. The administration of the β2-agonist, 
formoterol, despite its effect on muscle anabolism, does not have a significant effect on underlying skeletal growth.
(Aust Orthod J 2015; 31: 184-194)
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Introduction
Much has been written about the relationship between 
masticatory muscles and the growth and development 
of the underlying craniofacial skeletal structures. The 
mandibular musculature’s influence on craniofacial 
development is yet to be determined conclusively, 
although it is generally accepted that craniofacial 
shape is under the influence of both genetic and 
environmental factors. The functional matrix theory1,2 
describes the influence of soft tissues on facial form. It 
theorises that facial skeletal growth occurs in response 
to functional needs.
Previous research has used animal experimental 
models to explore the relationship between 
craniofacial morphology and muscle function. The 
studies have included changing the consistency of 
diet,2-5 physically removing the masseter,6,7-10 altering 
masticatory muscle function during growth,11-14 the 
removal of a sensory or motor neural branch,15-19 
pharmacological denervation,20,21 and altering the 
expression of muscle-specific genes.22 Decreased 
muscle function and muscle denervation results in 
structural and functional changes to skeletal muscle 
including atrophy and a decrease in force-producing 
capacity.23,24 The examination of the musculoskeletal 
interaction in craniofacial growth had been limited 
in surgical25 and extirpation6 studies in animals until 
the introduction of non-invasive muscle imaging 
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techniques, such as CT scanning,13,26-28 MRI,29,30 
and ultrasonography.30-33 Skeletal changes have tradi-
tionally been observed with radiography, in which 
a standardised cephalostat is used to maintain the 
position of animals while radiographic images are 
taken.2,16,17,34-36
Animal research based on the removal of the masseter 
muscle or surgical denervation has shown an overall 
reduction in mandibular dimensions, especially in 
ramus height. An opening of the gonial angle and 
localised changes in the skeletal insertions of the 
masseter muscle have also been shown.9,10,16,17,19,20,35-39 
Experimentally-induced masseter muscle atrophy 
replicates the muscular weakness often seen in 
neuromuscular diseases in humans, such as Duchenne 
and myotonic muscular dystrophy, both of which 
display characteristic craniofacial skeletal features 
associated with weaker orofacial musculature,40 41 or 
in patients with congenital absence of the facial nerve, 
such as in Moebius syndrome.42 Clinical observations 
in humans have shown that there is a relationship 
between weaker muscular bite force and increased 
underlying vertical facial dimension.43,44 In contrast 
with the effects of surgical denervation or muscle 
removal, the administration of anabolic steroids such 
as growth hormone and testosterone are reported to 
have had a positive effect on the growing craniofacial 
region.45-50
β2-adrenoceptor agonists (β2-agonists) were first 
developed to promote bronchodilation for asthmatic 
patients, but they are also acknowledged to have muscle 
growth-promoting effects, similar to those of anabolic 
steroids.51,52 The administration of β2-agonists has 
previously been shown to retard atrophy in denervated 
muscles.53-55 Clinical trials have highlighted the 
possible administration of a systemic β2-agonist for 
the treatment of various neuromuscular disorders, 
including muscular dystrophy, to improve muscle 
strength.56,57 Due to its high lipophilicity, a more 
recently synthesised β2-agonist, formoterol, has been 
shown to have an increased duration of action, as well 
as increased β2-adrenoceptor selectivity58 compared 
with traditional β2-agonists (such as clenbuterol).59,60
The intramuscular administration of β2-agonists 
allows site-specific drug delivery and may minimise 
the deleterious cardiac effects that often accompany 
the systemic administration in the treatment of 
asthma.61,62 To date, however, the skeletal and muscular 
effects of intramuscular administration of β2-agonists 
on the masseter muscle have not been widely reported. 
Therefore, the present study was designed to assess 
the effects of masseter muscle denervation, with or 
without the administration of a β2-agonist, on the 
dentofacial complex of the growing rat.
Materials and methods 
All experiments were approved by the Animal 
Experimentation Ethics Committee of the University 
of Melbourne (UM) (AECC number 0704146.1) 
and the Howard Florey Institute (HFI) Animal 
Experimentation Ethics Committee (AEC number 
07-067). All procedures were performed in accordance 
with the guidelines for The University of Melbourne 
Animal Welfare Committee and the Australian Code 
of Practice for the Care and Use of Animals for 
Scientific Purposes (2004).
Animals
Thirty-one four-week-old (70–140 g) Sprague-Dawley 
rats were housed for a period of eight weeks in 
standard cages within a pathogen-free environment in 
the Biological Research Facility at the University of 
Melbourne. The animals were kept under a 12:12 
hour light-dark cycle (light 0600–1800) with free 
access to food (rat chow) and water ad libitum. All rats 
were randomly assigned to either Surgical Sham (N = 
5), Denervated only (N = 9), Denervated + β2 agonist 
(N = 8), or β2 agonist only (N = 9) groups.
The Sprague-Dawley rat displays a known growth 
pattern and acknowledged motor movements and 
behavioural traits, including normal eating, drinking 
and grooming. Male rats were used because the male 
muscles are generally larger and easier to dissect. Four-
week-old rats were chosen, as the rat pups are usually 
weaned at 21 to 28 days. The subsequent period, from 
4 to 12 weeks, is a period of rapid growth, during 
which the rat is normally expected to double or triple 
in weight.63
Experimental procedure
The rats were anaesthetised with an intra-peritoneal 
(i.p) injection of a mixture of ketamine (225 mg/kg) 
and Xylazine (30 mg/kg), with supplemental doses 
administered, as necessary, to maintain an appropriate 
depth of anaesthesia, so that animals did not respond 
to tail or toe pinching.
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The process of dissection was performed under a ×20 
magnification stereomicroscope (World Precision 
Instruments Inc., Fl, USA). The left side of the rat 
was arbitrarily chosen as the experimental side in all 
animals. In the Surgical Sham and denervated groups, 
a small 3 to 10 mm incision was made over the area 
below and directly parallel to the zygomatic arch, 
between the eye and ear. The platysma and masseter 
muscle fibres were gently parted and the masseteric 
nerve was identified as it passed near the sigmoid notch 
of the mandibular coronoid process. A 5 mm section 
of the masseteric nerve and its branches were surgically 
removed en masse from the rats assigned to the 
denervated groups. The masseteric nerve was exposed, 
identified but not cut in animals from the Surgical 
Sham group. In animals from the Denervated + β2 
agonist group, the denervated masseter was injected 
i.m with formoterol (100 μm in saline; AstraZeneca, 
Molndal, Sweden). The incision was closed with a 
black silk suture and a 4-0 needle. Surgery was not 
performed on the β2-agonist only group. All rats 
recovered from the anaesthesia and rehydrated with 
subcutaneous isotonic saline, while their temperatures 
were monitored and maintained with a warming pad. 
Following recovery, the animals were returned to their 
cages and observed closely. Only wet mash and water 
was provided to the animals on the first day, after 
which, regular food was supplied. Every three days, 
the β2-agonist only and Denervated + β2-agonist 
groups were given a subcutaneous local injection of 
formoterol (100 μg in saline) into the left masseter 
muscle, for a total period of eight weeks.
To keep the animals still during the intramuscular 
injection, each was lightly anaesthetised. Initially, 
animals were placed in a clear plastic drop box, 
ventilated with 5% Isoflurane ((1 ml/ml) distributed 
by CENVET Australia) in a 1:1 mix of medical 
grade air and oxygen. Once anaesthetised, the rat 
was removed from the jar and a modified nose cone 
was placed over its snout to maintain anaesthesia 
via an inhaled-gas machine that supplied the animal 
with 2.5% Isoflurane (0.5 L/min). The animals were 
anaesthetised for approximately two to three minutes, 
which was long enough for the intramuscular 
injection of formoterol to be given. The animals were 
monitored until full recovery had been achieved.
At sacrifice, the rat was decapitated, skinned and 
carefully defleshed as much as possible until the skull 
remained. The skull was digitally radiographed with 
size #4 AT/K Scan X phosphor storage plates and 
scanner (Air Techniques Inc., NY, USA) at a standard 
anode-film distance of 25 cm in a custom-made 
polystyrene head and film holder. A Planmeca ‘intra’ 
x-ray machine (Planmeca Inc., IL, USA) was used to 
expose the phosphor storage plates, with the following 
settings used for all rats: 63 kV, 8 mA and exposure 
time of 0.2 seconds. All phosphor storage plates were 
scanned at high resolution (2872 × 3816 pixels). A 
standardised aluminium measurement gauge was 
placed on each radiographic film with holes cut at 1 
cm intervals along the entire film length. Three views 
were taken for each rat: a lateral view, with ear rod 
placed to transect both external auditory meatii of the 
rat at 90° to the film and x-ray source; a submento-
vertex view with the skull placed flat in the supine 
position; and right and left disarticulated hemi-
mandibles placed flat on each radiograph (Figure 1). 
Digitised radiographs were stored in DICOM format 
Figure 1. Examples of radiographs of rat skulls: (A) Submento-vertex view. (B) Lateral cephalometric view. (C) Hemi-mandibular view. Note on the hemi-
mandibular view: the difference between the experimental side hemi-mandibles from a denervated animal (upper) and a β2-agonist only animal (lower).
(A) (B) (C)
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and examined using the Adobe Photoshop CS3 v 
10.0.1 software (Adobe Systems Inc., CA, USA) at 
33.3% to 50% magnification. Brightness and contrast 
of the digital images were altered to provide the 
clearest possible picture of the radiographs. Sixteen 
measurements (3 angular and 13 linear), previously 
described in studies of craniofacial growth,23,59,61 were 
taken (Table I, Figure 2). All measurements were 
performed in a single-blinded manner.
Error of the Method
To determine error of the cephalometric measurement, 
duplicates of the 16 measurements from a random 
Figure 2. Cephalometric measurements taken from three radiographic views from each rat: (A) Submento-vertex view. (B) Lateral cephalometric view. (C) 





1 Total skull length, Po – A
2 Total face height, N – Pog
3 Sagittal diastema, premaxilla – incisor, Bu – U1
4 Upper face height, posterior height of snout, viscerocranium, N – U1
5 Anterior height of snout, viscerocranium, A – Pr
6 Lower face height, U1 – Pog
7 Mandibular angle, N – Po – Pog
8 Mandibular plane angle, N – Po/Gn – Pog
9 Total inter-zygomatic width (greatest posterior curvature)
10 Zygomatic arch, outside greatest curvature, to the midline, (a) LHS (b) RHS
11 Intercondylar width, condyle – condyle
12 Total length of bony mandible Go – b1
13 Height of ramus, S – Go
14 Mandibular height, inferior border of mandible – superior condyle
15 Lower ramus height, L (mandibular foramen) – Go
16 Hemi-mandibular plane, C – Go – Pog
Table II.  Facial landmark definitions.
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sample of five rats were taken at two different time 
points, one week apart. Dahlberg error64 was calculated 
for all measurements and paired t-tests used to 
compare measurements at the two time points. When 
compared, the Dahlberg range of error was 0.02 to 
0.10 mm for linear measurements, and 0.34 to 0.63° 
for angular measurements, which was considered 
small. No statistically significant differences were 
found between the two sets of measurements following 
the use of the paired t-test. 
Statistical analysis
All values are expressed as mean ± standard error of 
the mean unless otherwise specified. Experimental 
groups were compared with each other to determine 
significant differences using a one-way analysis of 
variance for the effects of sham surgery, formoterol 
administration and surgical denervation, or paired 
t-tests to compare left and right sides with each other 




Denervation resulted in significant atrophy of the 
experimental side muscle, and the animals had a 
characteristic longer and thinner appearance to their 
faces. β2-agonist administration caused significant 
hypertrophy of the masseter muscle and obviously 
shorter and broader heads in width and height. This 
was observed in the live and posthumously skinned 
animal heads. The overall body size of the animals 
was not noticeably different in any of the groups. The 
skulls of the Denervated only group also showed a 
mild skeletal asymmetry from the sagittal plane and 
skewed towards the denervated side (Figure 3).
Differences between the surgical sham and 
experimental groups
The mean final experimental-side cephalometric 
measurements for the surgical sham group and the 
three experimental groups are presented in Table II. 
The table indicates that, in relation to the final mean 
measurements for the surgical sham group, there were 
the following significant differences (p < 0.05):
•  mean decreases in total skull length (measurement 
1) of 2.3% and 2.8%, respectively, for the 
Denervation + β2-agonist and β2-agonist only 
groups;
•  mean decreases in the sagittal diastema (measure-
ment 3) of 5.9% and 4.8%, respectively, for the 
Denervation + β2-agonist and β2- agonist only 
groups; 
•  a mean decrease in total inter-zygomatic width 
(measurement 9) of 3.8% for the Denervation 
only group (Figure 4);
•  a mean decrease in the left zygomatic arch width 
to the midline (measurement 10a) of 4.5% for the 
Denervation only group;
(A) (B)
Figure 3. View of de-fleshed skulls: (A) View from above, showing a β2-agonist only specimen on the left and Denervated only specimen on the right. 
Note the difference in inter-zygomatic width transverse dimensions. In the Denervated specimen, there is also a slight skeletal asymmetry towards the 
experimental (left) side. (B) Left hemi-mandibles from a Denervated specimen (above) and a β2-agonist only specimen (below). Note the difference in size 
of the angular process and the condyle, the total height of the ramus, and the lower ramus height between the two specimens.
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•  a mean decrease in total bony length of the hemi-
mandible (measurement 12) of 4.8% for the 
Denervation only group;
•  a mean decrease in the hemi-mandibular height 
of the ramus (measurement 13) of 10.3% for the 
Denervation only group;
•  mean decreases in total hemi-mandibular 
height (measurement 14) of 11.3% and 7.5%, 
respectively, for the Denervation only and 
Denervation + β2-agonist groups;
•  a mean decrease in lower hemi-mandibular 
ramus height (measurement 15) of 11.8% for the 
Denervation only group;
•  mean increases in the angle of the hemi-mandible 
(measurement 16) of 7.2% and 3.7%, respectively, 
for the Denervation only and Denervation + β2-
agonist groups (Figure 5).
Differences between control and 
experimental sides in all groups
The mean final skeletal cephalometric measurements 
for experimental (left) and control (right) sides in 
the four groups are presented in Table III. The table 
reveals that, in comparison with the mean control side 
measurements, there were the following significant 
differences (p < 0.05) on the experimental sides:
•  a mean decrease in total mandibular bony length 
(measurement 12) of 3.5% in the Denervation 
only group;
•  mean decreases in the height of the mandibular 
ramus (measurement 13) of 2.7%, 9.0% and 5.2%, 
respectively, in the Surgical sham, Denervated only 
and the Denervated + β2-agonist groups; 
•  mean decreases in total height of the mandible 
(measurement 14) of 7.5% and 5.6%, respectively, 
Surgical sham Denervated Denervated + B2 agonist B2 agonist
Measurement Mean SEM Mean SEM Mean SEM Mean SEM
1 4.94 0.01 4.88   0.03 4.80* 0.02 4.83* 0.03
2 2.41 0.02 2.36   0.02 2.35 0.02 2.35 0.24
3 1.42 0.01 1.36   0.02 1.35* 0.01 1.34* 0.01
4 1.27 0.02 1.24   0.01 1.22 0.01 1.23 0.01
5 0.53 0.01 0.52   0.11 0.52 0.01 0.52 0.01
6 1.15 0.01 1.14   0.02 1.13 0.18 1.13 0.20
7 54.22 1.01 52.88   0.71 54.15 0.18 54.20 0.40
8 33.76 2.31 34.95   0.53 35.21 0.91 34.45 1.11
9 2.60 0.02 2.51*   0.02 2.60 0.02 2.61 0.03
10a 1.31 0.02 1.25*   0.01 1.29 0.01 1.30 0.01
10b 1.30 0.01 1.25   0.01 1.30 0.01 1.29 0.01
11 2.25 0.04 2.20   0.03 2.29 0.02 2.31 0.04
12 2.84 0.03 2.70*   0.03 2.73 0.02 2.82 0.02
13 1.21 0.02 1.10*   0.02 1.17 0.01 1.20 0.01
14 1.30 0.02 1.17*   0.03 1.21* 0.01 1.23 0.01
15 1.03 0.04 0.92*   0.03 1.00 0.02 1.05 0.01
16 92.9 0.62 100.08* 0.94 96.53 1.15 92.74 0.50
Table II.  Mean final experimental-side cephalometric measurements for the four study groups (CM 1 to 16).
Figure 4. Mean measurements for CM 10 for the four study groups.
Total inter-zygomatic width.
*p < 0.05 = significant difference compared to Surgical Sham
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in the Denervated only and Denervated + β2-
agonist groups;
•  mean decreases in lower ramus height (measurement 
15) of 8.3%, 12.4% and 5.9%, respectively, in the 
Surgical sham, Denervated only and Denervated + 
β2-agonist groups;
•  mean increases in the angle of the mandible 
(measurement 16) of 4.5% and 3.5%, respectively, 
in the Denervated only and Denervated + β2-
agonist groups (Figure 5).
Discussion
Mandibular plane angle increase following 
denervation of the masseter muscle
The results of previous studies have shown that 
significant changes can occur in the underlying 
facial skeleton following the removal of the masseter 
muscle65-68 or denervation of the masseteric nerve16,18,39 
in the rat. Moore believed that these growth differences 
in the mandible may arise from the post-surgical 
reduction in mechanical stresses generated by the 
muscles.35 An average increase of 6° in the mandibular 
plane angle in experimental animals compared 
with controls has been reported to follow masseter 
removal.37 A similar result was found in the present 
study, in which an average 7° increase was observed 
in the mandibular angle following denervation of the 
masseter in the growing animals. This would support 
the results of earlier studies of denervation in rats10 
and primates,17 in which weakened muscles resulted 
in more vertical growth patterns and an increase in the 
mandibular plane angle.
Figure 5. Mean measurement for CM 16 for the four study groups.
Left hemi-mandibular angle.
*p < 0.05 = significant difference compared to Surgical Sham
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Ramal height decrease following 
denervation of the masseter muscle
The results of the present study are consistent with 
a previously-reported decrease in ramal height of 
10% following the removal of the masseter muscle 
in rats,37 as well as those reported by Carter and 
Harkness,18 who also found significant changes in 
ramal height. The features of increased gonial angles 
and decreased ramal height correspond with the facial 
skeletal features of human subjects presenting with 
dolichofacial patterns. 
β2-agonist administration 
It has previously been shown that, following β2-
agonist administration in non-surgical subjects, 
muscle volume increased on average by 50%, muscle 
mass on average by 36%, and muscle fibre cross-
sectional area on average by 29%.65 In contrast, 
following surgical denervation of the masseter muscle, 
muscle volume decreased on average by 56%, muscle 
mass on average by 38%, and muscle fibre cross-
sectional area on average by 38%. Despite these likely 
significant increases or decreases in muscle mass, no 
equivalent positive or negative skeletal effects were 
found in the present study.
Overall facial skeletal changes following 
denervation of the masseter muscle
The skeletal effects of denervation of the masseter 
muscle in the present study were limited to the 
mandible and the transverse dimension of the 
skull. Significant decreases in the dimensions of the 
mandible were observed as the experimental hemi-
mandible had, on average, a shorter overall length and 
a decreased ramal height, especially in the area below 
the inferior alveolar canal. This is a significant area 
of insertion of the masseter muscle and also where 
the largest amount of height reduction was observed. 
Surgical denervation also resulted in statistically 
significant skeletal effects seen from the submento-
vertex view of the skull, with an average reduction in 
total inter-zygomatic width of 3.8%, especially on the 
experimental side. This is consistent with the general 
visual observation of a decrease in skull width and 
the results of previous studies which related muscle 
function to transverse skull dimensions in growing 
rats.69 It was noteworthy that the administration of 
the β2-agonist into the denervated masseter muscle 
resulted in only a small average decrease in total skull 
length and a decrease in the sagittal diastema, which 
was consistent with the general observation that the 
final rat heads were shorter in the antero-posterior 
dimension and wider in the transverse dimension than 
those of the controls. The results of previous studies 
suggested that, despite formoterol being administered 
i.m, it also seemed to have a local effect on other 
muscles in the craniofacial region, with significant 
increases seen especially in the mass and volume of 
the contralateral masseter muscle.66,67
Myostatin gene control of muscular 
development
It is generally accepted that the functioning muscles 
have a significant morphogenetic effect on the skeletal 
tissues to which they are attached. The myostatin gene 
is a potent negative regulator of muscle development, 
and a deficiency in the gene induces a dramatic increase 
in skeletal muscle mass resulting mainly from muscle 
hyperplasia and partly from hypertrophy. Myostatin-
deficient mice have been shown to produce relatively 
greater bite forces and to have, on average, 56% larger 
masseter muscles than controls.22,70 
Other possible effects on bone of β2-agonist 
administration 
The fact that there were only minor skeletal changes 
following only β2-agonist administration may be 
partly explained by a parallel alteration in the quality 
of the bone, such as increased density or cortication,65 
which has previously been demonstrated in mice.71 
There have been reports of the possible effects of 
β2-agonists as β-receptors exist in bone,72 and may 
influence bone growth by decreasing bone mineral 
content in growing rats.73 β2-agonists may induce 
alterations in the bony architecture and mechanical 
properties, opposing their own anabolic action and, in 
effect, negating the musculoskeletal interaction. 
Surgical Sham group 
An interesting finding of the present study was that, 
in the Surgical Sham group, significant differences 
were found between the sham experimental and 
control sides for ramus measurements (CM 13 and 
CM 16). It is possible that damage to the muscle or 
early post-operative inflammation and pain may have 
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limited muscular function during the experimental 
period and influenced underlying skeletal growth. 
This result was interesting because the Surgical Sham 
animals underwent masseteric nerve isolation, but 
not denervation. Surgical denervation is reported to 
remove approximately 70% of the muscle spindle 
afferent fibres from all masticatory muscles on the 
experimental side, and yet proprioceptive information 
from the skin, joints, teeth and remaining muscle 
spindle fibres is still acknowledged to provide 
feedback to support normal patterns of muscle 
activity.74 The masseter muscles contribute about 
54% of the total masticatory muscle mass in the 
rat, and, following denervation, the remaining 
masticatory muscles may compensate for any loss of 
function.63 These observations may, therefore, imply 
that a possible neurological mechanism is involved 
in bone remodelling and adaptation of the bone to 
the muscle.15 Such ‘neurotropic’ regulation would also 
integrate with Moss’s Functional Matrix Theory,75 in 
which nerves supply almost all so-called ‘capsular’ and 
‘periosteal’ functional matrices. 
Use of formoterol in treatment of muscle-
wasting diseases
That local administration of the β2-agonist had a 
negligible effect on the underlying skeleton may 
have implications for the treatment of Sarcopaenia 
or muscular dystrophy in growing patients, because 
iatrogenic craniofacial side-effects may be avoided.76,77 
Previous treatments for these disorders have included 
the administration of growth hormone, anabolic 
steroids and testosterone, all of which have been 
associated with unwanted effects on the growing 
craniofacial skeleton.50,78 If the administration of 
formoterol has little effect on skeletal growth in 
the human craniofacial region, it may be useful in 
the treatment of muscle wasting conditions such as 
Myotonic Dystrophy.
Many factors may contribute to or influence 
craniofacial skeletal growth. The level to which 
each factor might contribute, however, is not well 
understood and has so far been difficult to quantify. 
However, muscle function does seem to play a role 
in the determination of ultimate skeletal form. 
Mandibular size may be genetically pre-determined 
and, short of surgical lengthening, does appear 
resistant to increase beyond a pre-programmed size. 
The extent to which muscles influence growth has so 
far been difficult to measure and may never be fully 
understood. Other factors, such as ‘neurotropism’ 
or gene expression, may also contribute to overall 
craniofacial size and shape. Therefore, clinicians are 
advised to consider the mandibular muscles and their 
possible effects79,80 when planning and carrying out 
routine orthodontic treatment in growing patients.
Conclusions
Taking into account the limitations of any animal 
laboratory study, the following conclusions may be 
drawn:
1.  An increase in muscle size and mass following the 
administration of the β2-agonist, formoterol, had 
only limited effects on changes occurring in the 
underlying skeletal structures during growth.
2.  Denervation of the masseter muscle was associated 
with atrophy of the muscle itself, and significant 
skeletal changes in the craniofacial area during 
growth.
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